Please Wait...

ICAM 1 // Intercellular Adhesion Molecule 1

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

ICAM-1 is also known as CD54. This adhesion molecule, expressed at the surfaces of immune system and endothelial cells, is up-regulated by cytokine stimulation. ICAM-1 has 5 Ig-like domains, a transmembrane region and a small carboxyl-terminal cytoplasmic domain. ICAM1 bind two integrin: leukocyte function associated antigen (LFA1 and CD11a/CD18) and macrophage 1 antigen (Mac-1, CD11b/CD18) (Bella et al., 1998; Yang et al., 2004).

The extracellular domain of ICAM-1 can be detected in serum of healthy controls and levels are increased under disease. Serum ICAM-1 has been proposed as an indicator of inflammatory disease as soon as 1991 (Rothlein et al., 1991). The mechanism leading to the release of ICAM-1 is not fully understood and there is probably a shedding by membrane protease and an alternative RNA splicing (Witkowska and Borawska, 2004). It is possible that ADAM17 participate in the shedding of ICAM1 (in vitro studies) (Tsakadze et al., 2006).

 

SICAM-1 assay is a solid phase enzyme linked immunoassay which has been validated in the laboratory for measurement in human serum. The kit measures only the wild type allele of ICAM-1 and does not recognize ICAM-1 with the Kilifi mutation.

 

Bella, J., Kolatkar, P.R., Marlor, C.W., Greve, J.M., and Rossmann, M.G. (1998). The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc. Natl. Acad. Sci. U. S. A. 95, 4140–4145.

Rothlein, R., Mainolfi, E.A., Czajkowski, M., and Marlin, S.D. (1991). A form of circulating ICAM-1 in human serum. J. Immunol. 147, 3788–3793.

Tsakadze, N.L., Sithu, S.D., Sen, U., English, W.R., Murphy, G., and D’Souza, S.E. (2006). Tumor Necrosis Factor-α-converting Enzyme (TACE/ADAM-17) Mediates the Ectodomain Cleavage of Intercellular Adhesion Molecule-1 (ICAM-1). J. Biol. Chem. 281, 3157–3164.

Yang, Y., Jun, C.-D., Liu, J., Zhang, R., Joachimiak, A., Springer, T.A., and Wang, J. (2004). Structural Basis for Dimerization of ICAM-1 on the Cell Surface. Mol. Cell 14, 269–276.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @virtue_insight: #VIphv We are delighted to announce our new Gold Sponsor @bioclinica for our 16th Pharmacovigilance 2018 https://t.co/h…
bioclinica (6 hours ago)
RT @bioclinica: Tackling the costly issue of drug supply waste in clinical trials. Find out how Novo Nordisk & other global pharmas R embra…
bioclinica (6 hours ago)
Tackling the costly issue of drug supply waste in clinical trials. Find out how Novo Nordisk & other global pharmas… https://t.co/iW7Q9DfVgQ
bioclinica (6 days ago)
Background & key considerations to help #pharma prepare for new FDA blood pressure draft guidance issued in May. Ac… https://t.co/07dJeeD35E
bioclinica (2 weeks ago)
Tackling the costly issue of drug supply waste in clinical trials. Find out how Novo Nordisk & other global pharmas… https://t.co/tSx5tm2rgg
bioclinica (3 weeks ago)
DYK @bioclinica offers full-svc global clinical data mgmt svcs customizable to your study & program needs? Our high… https://t.co/dyXDiCtWd8
bioclinica (3 weeks ago)

Latest Blogs:

Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations